Intelligent Bio Solutions Inc. (INBS) - Total Liabilities
Based on the latest financial reports, Intelligent Bio Solutions Inc. (INBS) has total liabilities worth $6.61 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore INBS long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Intelligent Bio Solutions Inc. - Total Liabilities Trend (2017–2025)
This chart illustrates how Intelligent Bio Solutions Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Intelligent Bio Solutions Inc. asset portfolio.
Intelligent Bio Solutions Inc. Competitors by Total Liabilities
The table below lists competitors of Intelligent Bio Solutions Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BHB Brauholding Bayern-Mitte AG
F:B9B
|
Germany | €6.53 Million |
|
Curative Biotechnology Inc
NYSE MKT:CUBT
|
USA | $8.37 Million |
|
E79 Gold Mines Ltd
AU:E79
|
Australia | AU$387.78K |
|
OSR Holdings Inc
NASDAQ:OSRH
|
USA | $41.71 Million |
|
Lodestar Minerals Ltd
AU:LSR
|
Australia | AU$581.39K |
|
Paulic Meunerie Sa
PA:ALPAU
|
France | €10.66 Million |
|
Seoul Food Ind Co Ltd
KO:004415
|
Korea | ₩46.52 Billion |
|
Xylo Technologies Ltd.
NASDAQ:XYLO
|
USA | $19.96 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Intelligent Bio Solutions Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Intelligent Bio Solutions Inc. net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Intelligent Bio Solutions Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Intelligent Bio Solutions Inc. (2017–2025)
The table below shows the annual total liabilities of Intelligent Bio Solutions Inc. from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $5.44 Million | -2.85% |
| 2024-06-30 | $5.60 Million | -16.08% |
| 2023-06-30 | $6.67 Million | +14.83% |
| 2022-06-30 | $5.81 Million | -15.27% |
| 2021-06-30 | $6.85 Million | -10.89% |
| 2020-06-30 | $7.69 Million | +21.97% |
| 2019-06-30 | $6.31 Million | +13.41% |
| 2018-06-30 | $5.56 Million | -15.50% |
| 2017-06-30 | $6.58 Million | -- |
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The compan… Read more